This multiple-Pi, multiple-institution application for the competing renewal of the Pacific Northwest (PNW) Node of the NIDA Clinical Trials Network, submitted jointly by the University of Washington and Washington State University (WSU), has the primary aim of continuing the Node's active support of the CTN's mission to """"""""improve the quality of drug abuse treatment throughout the country using science as the vehicle"""""""", to conduct studies of the therapeutic effect of behavioral, pharmacological, and combined/integrated treatment interventions in rigorous, multi-site clinical trials to determine effectiveness across a broad range of community-based treatment settings and diversified patient populations, and to ensure the transfer of research results to physicians, clinicians, providers, policy makers, and patients. To meet these objectives, the PNW Node proposes to: 'Maintain/expand the effective, bidirectional partnerships among researchers, substance abuse treatment and healthcare providers, and policy makers that predate our entry into the CTN;'Maintain/expand our highly successful, well-established treatment research infrastructure;'Expand the Node's geographical reach, working with the CTSA-funded Institute of Translational Health Sciences (ITHS), to include the WWAMI region (Washington, Wyoming, Alaska, Montana, and Idaho);'Expand the Node's ethnic and demographic diversity by broadening the types of affiliated programs, expanding our focus on American Indians/Alaska Natives, and concentrating on rural communities/programs through our partnership with WSU's Program of Excellence on Rural Mental Health and Substance Abuse Treatment;Enhance the Node's capacity to conduct trials and respond more rapidly to shifting and emerging public health priorities by adding a number of larger, highly research-experienced, medically and psychiatrically focused partner organizations to complement our affiliated community-based substance abuse treatment programs;'Augment the clinical research expertise of the Node by adding a number of new affiliated Investigators;'Expand the Node's network of dissemination partners in order to provide research translation and training to a wider geographic and professional audience of providers, especially in primary care and rural settings. This new structure will allow us to capitalize on progress we have made and will enable us to continue to make significant contributions to the CTN's mission in the future.
Substance abuse is a major public health problem. Working with partnering community-based substance abuse, psychiatric, medical, and dissemination programs, the PNW Node contributes significantly to the CTN's developmental, evaluative, and translational research process to identify and disseminate empirically supported behavioral, pharmacological, and combined/integrated interventions for adoption by CTPs (Community Treatment Programs).
|Garrett, Sharon B; Doyle, Suzanne R; Peavy, K Michelle et al. (2018) Age differences in outcomes among patients in the ""Stimulant Abuser Groups to Engage in 12-Step"" (STAGE-12) intervention. J Subst Abuse Treat 84:21-29|
|Levran, Orna; Correa da Rosa, Joel; Randesi, Matthew et al. (2018) A non-coding CRHR2 SNP rs255105, a cis-eQTL for a downstream lincRNA AC005154.6, is associated with heroin addiction. PLoS One 13:e0199951|
|Barbosa-Leiker, Celestina; McPherson, Sterling; Layton, Matthew E et al. (2018) Sex differences in opioid use and medical issues during buprenorphine/naloxone treatment. Am J Drug Alcohol Abuse 44:488-496|
|Miguel, André Q C; Madruga, Clarice S; Cogo-Moreira, Hugo et al. (2018) Sociodemographic Characteristics, Patterns of Crack Use, Concomitant Substance Use Disorders, and Psychiatric Symptomatology in Treatment-Seeking Crack-Dependent Individuals in Brazil. J Psychoactive Drugs 50:367-372|
|Lee, Joshua D; Nunes Jr, Edward V; Novo, Patricia et al. (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391:309-318|
|McPherson, Sterling; Orr, Michael; Lederhos, Crystal et al. (2018) Decreases in smoking during treatment for methamphetamine-use disorders: preliminary evidence. Behav Pharmacol 29:370-374|
|Miguel, André Q C; Madruga, Clarice S; Simões, Viviane et al. (2018) Crack cocaine users views regarding treatment with contingency management in Brazil. Subst Abuse Treat Prev Policy 13:7|
|Newville, Howard; Sorensen, James L; Hatch-Maillette, Mary et al. (2018) Temporal Relationship of Sex Risk Behaviors and Substance Use Severity Among Men in Substance Use Treatment. J Sex Res 55:1056-1064|
|Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80|
|Wendt, Dennis C; Hallgren, Kevin A; Daley, Dennis C et al. (2017) Predictors and Outcomes of Twelve-Step Sponsorship of Stimulant Users: Secondary Analyses of a Multisite Randomized Clinical Trial. J Stud Alcohol Drugs 78:287-295|
Showing the most recent 10 out of 126 publications